Nifty 50 · Healthcare
Cipla
Cipla is a leading Indian pharmaceutical company with strengths in respiratory, HIV, and chronic therapies.
CIPLA · Healthcare
₹1,463.80
−13.20 (−0.89%)
Day High
₹1,477.00
Day Low
₹1,462.10
52W High
₹1,673.00
52W Low
₹1,165.70
Volume today: 7.65 L
PaisaTamil Consensus
HOLDScore 53/100 · Low confidence
Mixed signals across valuation and momentum. Existing investors may hold; new entries should wait for clarity.
12M Price Target
₹1,508
Low ₹1,332 · High ₹1,727
Analyst-style Breakdown
Strong Buy
0
Buy
0
Hold
14
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum55/100
1M +2.2%, 1Y -0.9%
Earnings Trend25/100
Latest quarter revenue ₹7.1k Cr, profit ₹789 Cr
Valuation75/100
P/E 28.0x vs sector median ~35x
Financial Quality65/100
ROE 14.5%, ROCE 13.2%
Technical Position55/100
Trading between 52W low 1166 and high 1673
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Jun 2026 | ₹7.1k Cr | ₹789 Cr | ₹9.77 | +7.3% | -35.4% |
| Mar 2026 | ₹6.5k Cr | ₹555 Cr | ₹6.87 | — | — |
| Dec 2025 | ₹7.0k Cr | ₹676 Cr | ₹8.37 | — | — |
| Jun 2025 | ₹6.8k Cr | ₹1.3k Cr | ₹16.07 | — | — |
| Mar 2025 | ₹6.6k Cr | ₹1.2k Cr | ₹15.13 | — | — |
Key Ratios
Market Cap
₹1.2 L Cr
P/E Ratio
28.0x
P/B Ratio
3.8x
ROE
14.5%
ROCE
13.2%
Dividend Yield
0.8%
Reference fundamentals for analysis. Verify latest quarterly results before making investment decisions.
Company Overview
Cipla manufactures generic drugs for India and export markets, with a growing US inhaler and complex generics portfolio.
Strengths
- +Strong India chronic therapy franchise
- +Respiratory product leadership
- +US complex generics pipeline
- +Consistent cash generation
Risks
- −US price erosion in generics
- −FDA compliance requirements
- −Competition in respiratory segment
- −Currency impact on exports
Investment Analysis
What to watch
- • Cipla is a defensive pharma play.
- • India prescription growth drives domestic revenue.
- • US inhaler approvals are upside catalysts.
| Industry | Pharmaceuticals |
|---|---|
| Sector | Healthcare |
| NSE Symbol | CIPLA |
| Index Weight | 0.65% |
| Market Cap | ₹1.2 L Cr |
Frequently Asked Questions
Yes. Cipla is a current constituent of the Nifty 50, which means it is among the 50 largest and most liquid stocks on the National Stock Exchange (NSE).